Dr. Cheng graduated from Shandong Second Medical University in 2008 with a degree in clinical medicine. In 2011, he obtained a master's degree in molecular cell biology from Ningbo University School of Medicine, and then worked as a clinician at Ningbo University Affiliated Kangning Hospital. During this period, he received standardized residency training and obtained the qualification of attending physician. After that, he obtained a doctorate in physiology from Xiamen University and joined Xiamen University Affiliated Zhongshan Hospital to engage in clinical and research work in translational medicine. Dr. Cheng's current field focuses on the role of epigenetic modification and immune inflammation in human diseases and clinical value evaluation. He has published dozens of research papers in internationally renowned journals, with thousands of citations.Dr. Cheng pioneered the discovery of the correlation between the methylation level of genes related to the human dopamine system and the risk of mental illness, and revealed the potential value of these abnormal biological markers in the identification and clinical treatment of mental illness. In addition, Dr. Cheng also used advanced electrophysiological intervention and cytokine detection technology to explore the relationship between changes in the level of inflammatory factors in the blood of patients during the treatment of mental illness and memory impairment, and proposed a new theoretical model for the risk of cognitive impairment in patients receiving electrophysiological intervention treatment.Dr. Cheng's research results revealed that The COMT polymorphisms act as a valuable biomarker with directive role in risperidone treatment for SCZ and identified a gender dimorphism of DRD4\COMT methylation in the susceptibility of SCZ. This epigenetic modification give hints to elaborate the pathological mechanisms of SCZ, and provide new biological aspects of Dopamine function-related genes. The aberrant methylation of DRD4\COMT gene act as valuable gender-specific biomarkers to monitor the risk and development of SCZ. Dr. Cheng also demonstrated higher levels of infammatory cytokines in the peripheral blood are associated with cognitive impairment risk in MDD patients receiving MECT. This fnding contributes to the neurobiological theory of infammatory cytokineinduced cognitive dysfunction in MDD.